Company News Summary | 29 Jun 2020

Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified

Starpharma Holdings Announces DEP irinotecan Boosts Immuno-Oncology in Colon Cancer Models

09:22:00 | Associate analysts

Original annuncemenet:DEP irinotecan boosts immuno-oncology in colon cancer models

Starpharma Holdings announced its SN-38 nanoparticle, DEP irinotecan in combination with an immunooncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC mode. IO agents are important treatments in several major cancers and the market for these agents is expected to exceed US$55bn by 2025, and include Merck's Keytruda, BMS' Yervoy and AstraZeneca's Imfinzi.

This report appeared on 2021 Morningstar Australasia Pty Limited

© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").

DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain appropriate financial, legal and taxation advice before making any financial investment decision. If applicable, investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Please refer to our Financial Services Guide (FSG) for more information at FSG or phone Morningstar on 1800 03 44 55 to request a copy. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for any use or distribution of any of this information

DISCLOSURE: Employees may have an interest in the securities discussed in this report.